Thus, (i) microtubule affinity-regulating kinase 4 (MARK4), (ii) Rho-associated coiled-coil-containing protein kinase I/II (ROCKI/II) and (iii) cyclin-dependent kinase 5 (CDK5) were considered for discussion, since these proteins are innovative as AD therapeutic targets, according to recent state of the art research, and, simultaneously, have not yet been considered in terms of combination with 5-HT6R activity. Here, HTR6 is linked to Alzheimer disease.